1. World Health Organisation Meeting of the Strategic Advisory Group of Experts on Immunisation April 2014 – Conclusions and Recommendations. Weekly Epidemiological Record, 21(89), 2014, pp. 221–236.
2. Human Papillomavirus Vaccines: WHO Position Paper, October 2014. Weekly Epidemiological Record, 89(43), 2014, pp. 456–492.
3. EPAR Summary for the Public Gardasil 9 〈http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003852/WC500189114.pdf〉.
4. European Medicines Agency 21 November 2013 EMA/789820/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment Report Cervarix 〈http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000721/WC500160885.pdf〉.
5. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP);Centers for Disease Control Prevention;MMWR Morb. Mortal. Wkly. Rep.,2010